Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder.

ABSTRACT:

Objective

Current medications for alcohol use disorder do not target brain noradrenergic pathways. Theoretical and preclinical evidence suggests that noradrenergic circuits may be involved in alcohol reinforcement and relapse. After a positive pilot study, the authors tested the α-1 adrenergic receptor antagonist prazosin to treat alcohol use disorder in a larger sample.

Method

Ninety-two participants with alcohol use disorder but without posttraumatic stress disorder were randomly assigned to receive prazosin or placebo in a 12-week double-blind study. Medication was titrated to a target dosing schedule of 4 mg in the morning, 4 mg in the afternoon, and 8 mg at bedtime by the end of week 2. The behavioral platform was medical management. Participants provided daily data on

SUBMITTER: Simpson TL 

PROVIDER: S-EPMC6395537 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature